SCHEMBL2843149

SCHEMBL2843149

C#CCCCOc1ccc(C=O)cc1OC

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.72
MAPT P10636 10/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
LMNA P02545 4/20 0.59
HTT P42858 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
ALDH1A1 P00352 12/20 0.58
HPGD P15428 7/20 0.58
TSHR P16473 1/20 0.58
CYP2C9 P11712 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP2D6 P10635 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
HSP90AA1 P07900 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845883 0.96 FDPS (0.70) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL2842951 0.94 FDPS (0.63) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL2845993 0.93 FDPS (0.74) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL2841820 0.90 FDPS (0.61) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL2851023 0.87 FDPS (0.65) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL9442186 0.86 FDPS (0.90) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL8719147 0.85 FDPS (0.87) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL9442183 0.85 FDPS (0.87) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL5973815 0.85 FDPS (1.00) FDPSMAPTSMN1; SMN2LMNAHTT
SCHEMBL16272286 0.84 FDPS (0.49) FDPSMAPTSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2799427-B1 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2018-07-04 EP disclosed
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 US disclosed
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 US disclosed
EP-2799427-A1 Therapeutic compounds Fibrotech Therapeutics PTY LTD (AU) 2014-11-05 EP disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 US disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 US disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 US disclosed
EP-2035369-B1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-06-25 EP disclosed
EP-2035369-B1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-06-25 EP disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
EP-2035369-A1 THERAPEUTIC COMPOUNDS Fibrotech Therapeutics PTY LTD (AU) 2009-03-18 EP disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357628-A1 THERAPEUTIC COMPOUNDS NFATC1, AADAC, NAT1 FDPS 681/4885MAPT 2890/4885SMN1; SMN2 2743/4885
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC FDPS 668/4885MAPT 3019/4885SMN1; SMN2 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.